Podcasts about cardiac

Welcome to Dev Game Club, where this week we try something a little different. Unattached to any particular game, we chat with Ed Fries, a long-time video game developer most well-known for his work  shepherding the early days of Xbox and Microsoft Game Studios. We talk about five games of his early years that particularly affected him. Dev Game Club looks at classic video games and plays through them over several episodes, providing commentary. Podcast breakdown: 1:16:35 Break 1:16:48 Outro Issues covered: a new model for interviews, productivity software wars, a child of engineers, Lunar Lander on a calculator, 6800-based kit computer and programming in assembly, cardboard computer, jumping from BASIC to assembly language, using a print terminal, modem sounds, competitive Asteroids, the first real video game, oscilloscopes and radar, complaining to the dentist, inspiring a generation of programmers and engineers, learning by typing from magazines, the 8-bit microprocessor, getting a 6502 square root routine from Woz, using a computer terminal, an intro to Rogue and its procedural elements, a things-going-wrong simulator, "there were not that many games in the world," building a game for different player types, the D programming language and other alphabetic languages, a short remembrance of Dani Bunten Berry, Multiple Use Labor Elements, how M.U.L.E. plays, screwing your buddies, similarities to Euro strategy games, the auction phase, crystite mining, a literary game, the first original IP character in a video game, moving from real caves to fantasy, some connections, album covers from EA, expensive personal computers. Games, people, and influences mentioned or discussed: Frogger, ROMox, The Princess and the Frog, Ant Eater, Sea Chase, Tom and Ed's Bogus Software, Tom Saxton, Sucker Punch, Microsoft, Ender's Game, Phil Spencer, Xbox, Bungie, Ensemble Studios, Rare Limited, World of Warcraft, Gabe Newell, Atari 2600, Halo, 1Up Ventures Fund, Psychonauts, Keeper, Tim Schafer, Boeing, Digital Equipment Corporation, Lunar Lander, CARDIAC, Nintendo Labo, Apple ][, Atari 800, Space Wars, Asteroids, Nolan Bushnell, Ampex, Ted Dabney, Computer Space, Nutting Associates, Computer Trivia, Pong, Homeworld, Steve Wozniak, Rogue, Defeating Games for Charity, Dark Souls, HACK, PDP-11/VAX, Epyx, Walter Bright, Sid Meier, Civilization, Bruce Shelley, Age of Empires, M.U.L.E., Dani Bunten Berry, Seven Cities of Gold, Settlers of Cataan, Diplomacy, AJ Redmer, Maxis, Will Wright, Dungeon/Zork, Don Daglow, Tim Anderson, Colossal Cave Adventure/Advent, Infocom, Frank Cifaldi, Video Game History Foundation, Kate Willaert, Will Crowther, Don Woods, Mike Haas, Andrei Alexandrescu, 2001: A Space Odyssey, Populous, The Bard's Tale, Outer Wilds, Kirk Hamilton, Aaron Evers, Mark Garcia.  Next time: TBA! or more Pikmin TTDS: 40m 6s Links: Ant Eater source  Princess and Frog source Sea Chase source  Nitro source Errata: I misspoke with respect to the co-inventor of D, it was Andrei Alexandrescu. We regret the error. Twitch: timlongojr and twinsunscorp  YouTube  Discord  DevGameClub@gmail.com 

Fewer than 20% of women take part in cardiac rehabilitation (CR) programs, which is one of the most proven ways to recover and prevent another heart event Women who complete cardiac rehab lower their risk of hospitalization by up to 42% and reduce their risk of death from heart disease by as much as 58%, gaining both longer life and better quality of life Referral bias is a major reason for low participation — women are referred for cardiac rehab less often than men, and rates are even lower among Black, Hispanic, and Asian women, where participation averages just 10% to 12% Automatic referrals, flexible scheduling, home-based or hybrid options, and women-only programs are powerful, research-backed strategies that dramatically increase enrollment and completion rates Cardiac rehab isn't just exercise — it's a personalized recovery plan that rebuilds heart strength, lowers stress, and restores confidence, giving women a structured way to take back control of their health and their future

Logan Davidson joins the show to talk about the fast-moving world of Ibogaine in American and why state-based leadership is shaping the future of psychedelic reform. Davidson is the executive director of Texans for Greater Mental Health, the legislative director at VETS, and a key strategist behind Texas' landmark interest in ibogaine research. He also advises for Americans for Ibogaine. His work sits at the intersection of science, policy, and lived experience, and this conversation offers a clear look into what is happening right now. Early Themes: The Rise of State Advocacy Davidson explains how he entered politics at nineteen and how his professional path merged with psychedelic policy work during the 2021 Texas legislative session. Through that first bill, he saw how science, bipartisan cooperation, and strong local leadership could advance major reform. Early discussion focuses on: How Texas became the first state to pass a major psychedelic research bill Why ibogaine became a central focus How the special operations community helped shift political momentum The personal mental health stories that shaped Davidson's commitment This section also highlights how Americans for Ibogaine entered the conversation through veterans, researchers, and state lawmakers who felt the urgency of the opioid crisis and traumatic brain injury. Core Insights: Ibogaine, Risk, and the New Research Model In the middle portion of the episode, Davidson breaks down the strategy, challenges, and promise behind ibogaine research and state-based policy innovation. Key insights include: The unique bipartisan environment in Texas Why stories from veterans and spouses moved lawmakers The importance of medical screening for cardiac risk Why research is essential for safety How states can use funding, revenue sharing, and public health goals to shape future access What policymakers are watching right now Effectiveness for opioid use disorder Data from traumatic brain injury studies Cardiac safety protocols The risk of untreated depression and addiction The national security implications of forcing service members to seek illegal care Davidson also explains why removing the psychedelic experience from the molecule remains controversial and why many researchers believe the full experience matters. Later Discussion and Takeaways: The Road Ahead for American Ibogaine In the final part of the conversation, Davidson speaks about the future of American Ibogaine and the broader psychedelic field. He outlines why local leadership matters, why federal funding, like what Psychedelic Medicine Coalition is supporting, could be the next major tipping point, and how big pharmaceutical companies may eventually enter the space through acquisitions or proprietary molecule development. Concrete takeaways include: States should expect clear benefits: lower-cost treatments, shared revenue, and local control Community leaders, not outsiders, often drive legislative wins The need for long-term safety data remains National security concerns highlight why regulated access must expand Federal research money could radically transform the pace and scale of studies He also encourages listeners to join or build local organizations, since nearly every major win comes from people who live in the state pushing from the ground up. Frequently Asked Questions Is Ibogaine safe? Ibogaine has cardiac risks that require medical screening and careful monitoring. Researchers stress that safety improves with proper protocols and more clinical data. Why is Ibogaine important for veterans? Many special operations veterans report major benefits for traumatic brain injury, PTSD, and addiction. Their stories have driven political momentum. How are states involved in Ibogaine research? States like Texas are funding clinical trials, drug development, shaping policy, and exploring revenue and access models to support long-term public health benefits. Will Ibogaine become federally supported in America? New federal interest, including major grants and bipartisan discussions, suggests that broader support may be coming in the next few years. Closing Thoughts This episode shows why the work of Logan Davidson sits at the center of today's psychedelic resurgence. It highlights a complex but hopeful moment where science, policy, and lived experience are beginning to align. As American Ibogaine research expands, state leaders, clinicians, veterans, and advocates all have a role in shaping a safer and more effective future for these treatments.

12/1/2025 | Cardiac

12/1/2025 | Cardiac

Enlace del curso: https://app.behindtheknife.org/premium/repaso-para-el-examen-de-certificaci-n-en-cirug-a-general Behind the Knife es el podcast quirúrgico líder en el mundo y una plataforma de educación quirúrgica. Nuestra misión es crear contenido innovador de educación quirúrgica que sea accesible para todos. Estamos muy emocionados de expandirnos al público hispanohablante y ofrecerles 4 episodios de muestra de nuestro Curso de Repaso para el examen de certificación de Cirugía General. Hoy, escucharás un caso de muestra de este curso de repaso en audio, que incluye 100 escenarios. El curso tiene un formato emocionante y completamente único. Cada uno de los 100 caso consta de dos partes. La primera parte es un caso oral perfectamente ejecutado que imita la realidad. Cada caso tiene una duración de cinco a siete minutos e incluye una variedad de tácticas y estilos. Si logras alcanzar este nivel de desempeño en tu preparación, seguramente aprobarás el examen de certificación con éxito. La segunda parte introduce comentarios de alto rendimiento para cada escenario. Estos comentarios incluyen consejos y trucos para ayudarte a dominar los escenarios más desafiantes, además de una enseñanza práctica y fácil de entender que cubre los temas más confusos que enfrentamos como cirujanos generales. Estamos seguros de que encontrarás este enfoque único de doble formato como una forma altamente efectiva de prepararte para el examen. Nuestro contenido está disponible en nuestras aplicaciones para iOS y Android y en nuestro sitio web (behindtheknife.org). Por favor, consulta las notas del programa para más información. Nos encantaría escuchar tus comentarios sobre este episodio enviando un correo electrónico a hello@behindtheknife.org y apreciamos tu ayuda para difundir la palabra entre tus colegas si disfrutas del material. Este contenido incluye 97 descripciones operatorias para todos los procedimientos comunes —y la mayoría de los poco comunes— incluidos en el Currículo de Cirugía General SCORE. Cada descripción está diseñada para ayudar a los candidatos a prepararse de manera eficaz para el Examen de Certificación en Cirugía General. presentadores de podcast: - Auri P. Garcia Gonzalez, MD PhD nació en San Juan, Puerto Rico, y se trasladó a los Estados Unidos en el 2012 para sus estudios graduados. Actualmente, es estudiante de post-grado en cirugía general en Duke University. - Diego Schaps, MD, MPH es un residente de cirugía general en Duke y nació en Miami, en el estado de la Florida. Sus padres nacieron en El Salvador. Disclaimer: Los productos de contenido de Behind the Knife son únicamente para fines educativos. No diagnosticamos, tratamos ni ofrecemos consejos específicos para pacientes. ------ Behind the Knife is the world's leading surgical podcast and surgical education platform.  Our mission is to create innovative surgical education content that is accessible to all.  We are very excited to expand into the spanish audience and bring you 4 sample episodes of our General Surgery Oral Board Review Course which will be released over the course of the next week. Today, you'll hear a sample scenario from this comprehensive audio review course which includes 100 scenarios.  The course has an exciting and entirely unique format. Each of the 100 scenarios includes two parts. The first part is a perfectly executed oral board scenario that mimics the real thing. Scenarios are five to seven minutes long and include a variety of tactics and styles. If you're able to achieve this level of performance in your preparation, you are sure to pass the oral exam with flying colors. The second part introduces high yield commentary to each scenario. This commentary includes tips and tricks to help you dominate the most challenging scenarios in addition to practical, easy to understand teaching that covers the most confusing topics that we face as general surgeons. We are confident you will find this unique dual format approach a highly effective way to prepare for the test. The course contains crisp, concise operative descriptions that cover all SCORE common topics and and most SCORE uncommon topics. Our content is available on our iOS and Android apps and website (behindtheknife.org).  Please check the show notes for more information. We would love to hear your feedback by emailing hello@behindtheknife.org and appreciate your help spreading the word to your colleagues if you enjoy the material. Hosts: - Auri P. Garcia Gonzalez, MD PhD was born and raised in San Juan, Puerto Rico and moved to the US in 2012 for graduate studies. At present, she is a surgical resident at Duke University. - Diego Schaps, MD, MPH is a general surgery resident at Duke and was born in Miami, Florida. His parents were born in El Salvador. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Send us a textA chaotic overtime win over Arizona shows both sides of this team: careless turnovers and ice-cold clutch throws. We weigh late-game analytics, celebrate a key return on offense, and map the most interesting playoff path Jacksonville has seen in years.• Wildcard position improving with many winnable games ahead• Trevor Lawrence volatility and late-game efficiency• Breakdown of Lawrence's picks and the coverage adjustments he saw• Brenton Strange's return opening the middle of the field• Parker Washington's chemistry and special teams impact• Defensive pressure spike, DB blitzes, and front improvements• Coaching aggression on fourth down and clock nuances• AFC playoff matchups to target and avoid• Titans preview and trap-game risk managementUse the promo code Touchdown Jaguars on SeatGeek to save $20 on your first eligible SeatGeek purchaseDon't forget to like, share, and give the podcast five stars on your podcast playerTouchdown Jaguars Linktree James Johnson and Phil Barrera bring you the best and most up to date Jacksonville Jaguars news. "Touchdown Jaguars!" is a tribute to the prospective ownership group "Touchdown Jacksonville!" In 1991, the NFL announced plans to add two expansion teams and "Touchdown Jacksonville!" announced its bid for a team, and Jacksonville was ultimately chosen as one of five finalists. In November 1993, the NFL owners voted 26–2 in favor of awarding the 30th franchise to Jacksonville. James and Phil have been fans of the franchise ever since and have had the honor (and sometimes dishonor) of covering the team professionally since 2017. The rest as they say, is history.

“Can you really be thankful when your heart is breaking?”In this powerful Thanksgiving episode of Female Voices: Life & Loss, Teresa and LaWayna open up about navigating grief during the holidays and how gratitude can coexist with pain. From personal stories of loss to a helicopter ride filled with fear and prayer, they share authentic perspectives on reframing, community, and starting small gratitude practices that help bring calm to an overwhelmed mind.Whether you're grieving someone you love, struggling financially, or just feeling disconnected heading into the holidays—this conversation will remind you that you're not alone, and you can hold grief and grace at the same time.Quotes worth remembering● “You can absolutely have gratitude and be grieving at the same time—we are complicated human beings.” – LaWayna ● “Sometimes instead of asking ‘What am I grateful for?' ask ‘What do I have?'” – Teresa● “When we slow down and breathe, even for two minutes, the body begins to restore.” – Teresa● “I told the Lord, help your little sad child today.” – LaWayna ● “Maybe start with the ungrateful list before the grateful one.” – LaWayna Topics Covered● Navigating grief during the holiday season● How gratitude affects our brain chemistry and cortisol levels● Different gratitude practices (journaling, prayer, spoken word, connection)● The power of community in healing (AA, friendships, families)● Reframing and slowing down to be present● Adventuring outside comfort zones as an act of livingKey Takeaways● You can hold both grief and gratitude at the same time. Healing doesn't require pretending you're okay.● Starting small helps: Even a 2-minute breathing or gratitude moment can help reduce stress.● There is no one right way to practice gratitude. Journaling, prayer, speaking, community—find what works for you.● Reframing can shift mental state. Sometimes “What do I have?” is easier than “What am I grateful for?”● Getting emotions out (even the negative ones) may help. Try writing an “ungrateful list” before moving into gratitude. Suggested Timestamps00:00 – Welcome & Thanksgiving intro02:13 – Acknowledging current struggles (financial, loss, food scarcity)05:04 – Josh's gratitude practice through AA community07:02 – Holding grief and gratitude together11:19 – Scientific impact of gratitude (dopamine, serotonin)14:25 – How grief floods the body with cortisol17:07 – Breathing practice and beginning with 2 minutes22:49 – Helicopter moment: prayer, fear, and reframing27:30 – “What do I have?” as a gratitude entry point28:00 – Ungrateful list exercise29:18 – Tool announcement for listeners30:21 – Thanksgiving photos & family traditions32:21 – Closing remarks & listener engagementMentions & Shoutouts● AA Support Group – demonstrating accountability and morning gratitude list.Episode Extras●

Joined on this episode by two awesome guests. One of my favorite people on the planet in Chief Frank Leeb, and the other one that I am excited to meet and have an awesome conversation with in Kory Pearn.  We plan to talk about all the issues that can blindside us in the fire-service. The mission of Crackyl magazine.  Cancer, Cardiac, Physical fitness. How can we ensure that a young firefighter becomes an old firefighter! an informative conversation and as always the best laid plans of me and my guests was beautifully derailed by the awesome question from the Scrap audience.  

Dystrophinopathies are heritable muscle disorders caused by pathogenic variants in the DMD gene, leading to progressive muscle breakdown, proximal weakness, cardiomyopathy, and respiratory failure. Diagnosis and management are evolving areas of neuromuscular neurology. In this episode, Kait Nevel, MD, speaks with Divya Jayaraman, MD, PhD, an author of the article "Dystrophinopathies" in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Jayaraman is an assistant professor of neurology and pediatrics in the division of child neurology at the Columbia University Irving Medical Center in New York, New York. Additional Resources Read the article: Dystrophinopathies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today I'm interviewing Dr Divya Jayaraman about her article on dystrophinopathies, which she wrote with Dr Partha Ghosh. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Divya, welcome to the podcast, and please introduce yourself to the audience. Dr Jayaraman: Thank you so much, Dr Nevel. My name is Divya, and I am an assistant professor of Neurology and Pediatrics at Columbia University Irving Medical Center, and also an attending physician in the Pediatric Neuromuscular program there. In that capacity, I see patients with pediatric neuromuscular disorders and also some general pediatric neurology patients and also do research, primarily clinical research and clinical trials on pediatric neuromuscular disorders. Dr Nevel: Wonderful. Thank you for sharing that background with us. To set us on the same page for our discussion, before we get into some more details of the article, perhaps, could you start with some definitions? What comprises the dystrophinopathies? What are some of the core features? Dr Jayaraman: So, the dystrophinopathies, I like that term because it is a smaller subset from the muscular dystrophies. The dystrophinopathies are a spectrum of clinical phenotypes that are all associated with mutations in the DMD gene on chromosome X. So, that includes DMD---or, Duchenne muscular dystrophy---, Becker muscular dystrophy, intermediate muscular dystrophy (which falls in between the two), dilated cardiomyopathy, asymptomatic hyperCKemia, and manifesting female carriers. In terms of the core features of these conditions, so, there's some variability, weakness being prominent in Duchenne and also Becker. The asymptomatic hyperCKemia, on the other hand, may have minimal symptoms and might be found incidentally by just having a high CK on their labs. They all will have some degree of elevated CK. The dilated cardiomyopathy patients, and also the Becker patients to a lesser degree, will have cardiac involvement out of proportion to skeletal muscle involvement, and then the manifesting carriers likewise can have elevated CK and prominent cardiac involvement as well as some milder weakness. Dr Nevel: Now that we have some definitions, for the practicing neurologists out there, what do you think is the most important takeaway from your article about the dystrophinopathies? Dr Jayaraman: I like this question because it suggests that there's something that, really, any neurologist could do to help us pick up these patients sooner. And the big takeaway I want everyone to get from this is to check the CK, or creatine kinase, level. It's a simple, cheap, easy test that anyone can order, and it really helps us a lot in terms of setting the patient on the diagnostic odyssey. And in terms of whom you should be thinking about checking a CK in, obviously patients who present with some of the classic clinical features of Duchenne muscular dystrophy. This would include young boys who have toe walking, as they're presenting, sign; or motor delayed, delayed walking. They may have calf hypertrophy, which is what we say nowadays. You might have seen calf pseudohypertrophy in your neurology textbooks, but we just say calf hypertrophy now. Or patients can often have a Gowers sign or Gowers maneuver, which is named after a person called Gowers who described this phenomenon where the child will basically turn over and use their hands on the floor to stand up, usually with a wide-based gait, and then they'll sort of march their hands up their legs. That's the sort of classic Gowers maneuver. There are modified versions of that as well. So, if anyone presents with this classic presentation, for sure the best first step is to check a CK. But I would also think about checking a CK for some atypical cases. For example, any boy with any kind of motor or speech delay for whom you might not necessarily be thinking about a muscle disorder, it's always good practice to check a CK. Even a boy with autism for whom you may not get a good clinical exam. This patient might present to a general pediatric neurology clinic. I always check a CK in those patients, and you'll pick up a lot of cases that way. For the adult folks in particular, the adult neurologist, a female patient could show up in your clinic with asymptomatic hyperCKemia. And I think it's an important differential to think about for them because this could have implications not just for their own cardiac risks, but also for their family planning. Dr Nevel: So, tell us a little bit more about the timing of diagnosis. Biggest takeaway: check a CK if this is anywhere on your radar, even if somewhat of an atypical case. Why is it so important to get kiddos started on that diagnostic odyssey, as you called it, early? Dr Jayaraman: This is especially important for kids because if they especially get a Duchenne muscular dystrophy diagnosis, you might be making them eligible for treatments that we've had for some time, and also treatments that were not available earlier that hinge on making that diagnosis. So, for example, people may be skeptical about steroids, but there's population data to suggest that initiation and implementation of steroids could delay the onset of loss of ambulation as much as three years. So, you don't want to deprive patients of the chance to get that. And then all the newer emerging therapies---which we'll be talking about later, I'm sure---require a Duchenne muscular dystrophy diagnosis. So, that's why it's so important to check a CK, have this on your radar, and then get them to a good specialist. Dr Nevel: I know that you alluded already, or shared a few of the kind of exam paroles or findings among patients with dystrophinopathy. But could you share with us a little bit more how you approach these patients in the clinic who are presenting with muscle weakness, perhaps? And how do you approach this or think about this in terms of ways to potentially differentiate between a dystrophinopathy versus another cause of motor weakness or delay? Dr Jayaraman: It's helpful to think through the neuraxis and what kinds of disorders can present along that neuraxis. A major differential that I'm always thinking about when I'm seeing a child with proximal weakness is spinal muscular atrophy, which is a genetic anterior horn cell disorder that can also present in this age group. And some of the key differences there would be things like reflexes. So, you should have dropped reflexes in spinal muscular atrophy. In DMD, surprisingly, they might have preserved Achilles reflexes even if their patellar reflexes are lost. It may only be much later that they go on to lose their Achilles reflex. So, if you can get an Achilles reflex, that's quite reassuring, and if you cannot, then you need to be thinking about spinal muscular atrophy. They can both have low muscle tone and can present quite similarly, including with proximal weakness, and can even have neck flexion weakness. So, this is an important distinction to make. The reason for that is, obviously there are treatments for both conditions, but for spinal muscular atrophy, timing is very, very important. Time is motor neurons, so the sooner you make that diagnosis the better. Other considerations would be the congenital muscular dystrophies. So, for those that they tend to present a lot younger, like in infancy or very early on, and they can have much, much higher CKS in that age range than a comparable Duchenne or Becker muscular dystrophy patient. They can also have other involvement of the central nervous system that you wouldn't see in the dystrophinopathies, for example. My mnemonic for the congenital muscular dystrophies is muscle-eye-brain disease, which is one of the subtypes. So, you think about muscle involvement, eye involvement, and brain involvement. So, they need an ophthalmology valve. They can have brain malformations, which you typically don't see in the dystrophinopathies. I think those are some of the major considerations that I have. Obviously, it's always good to think about the rest of the neuraxis as well. Like, could this be a central nervous system process? Do they have upper motor neuron signs? But that's just using all of your exam tools as a neurologist. Dr Nevel: Yeah, absolutely. So, let's say you have a patient in clinic and you suspect they may have a dystrophinopathy. What is your next diagnostic step after your exam? Maybe you have an elevated CK and you've met with the patient. What comes next? Dr Jayaraman: Great question. So, after the CK, my next step is to go to genetics. And this is a bit of a change in practice over time. In the past we would go from the CK to the muscle biopsy before genetic testing was standard. And I think now, especially in kids, we want to try and spare them invasive procedures where possible. So, genetic testing would be the next step. There are a few no-charge, sponsored testing programs for the dystrophinopathies and also for some of the differential diagnosis that I mentioned. And I think we'll be including links to websites for all of these in the final version of the published article. So, those are a good starting point for a genetic workup. It's really important to know that, you know, deletions and duplications are a very common type of mutation in the DMD gene. And so, if you just do a very broad testing, like whole exome, you might miss some of those duplications and deletions. And it's important to include both checking for duplications and deletions, and also making sure that the DMD gene is sequenced. So always look at whatever genetic test you're ordering and making sure that it's actually going to do what you want it to do. After genetics, I think that the sort of natural question is, what if things are not clear after the genetics for some reason? We still use biopsy in this day and age, but we save it for those cases where it's not entirely clear or maybe the phenotype is a little bit discordant from the genotype. So, for mutations that disrupt the reading frame, those tend to cause Duchenne muscular dystrophy, whereas mutations that preserve the reading frame tend to cause Becker muscular dystrophy. There are some important exceptions to this, which is where muscle biopsy can be especially helpful in sorting it out. So, for example, there are some early mutations early in the DMD gene where, basically, they find an alternate start codon or an initiation codon to continue with transcription and translation. So, you end up forming a largely functional, somewhat truncated protein that gives you more of a milder Becker phenotype. On the other hand, you can have some non-frameshift or inframe mutations that preserve the reading frame, but because they disrupt a very key domain in the protein that's really crucial for its function, you can actually end up with a much more severe Duchennelike phenotype. So, for these sorts of cases, you might know a priori you're dealing with them, but might just be a child who is who you think has DMD has a mutation that's showed up on testing. There isn't enough in the literature to point you one way or another, but they look maybe a little milder than you would expect. That would be a good kid to do a biopsy in because there are treatment decisions that hinge on this. There are treatments that are only for Duchenne that someone with a milder phenotype would not be eligible for. Dr Nevel: So, that kind of stepwise approach, but maybe not all kids need a muscle biopsy is what I'm hearing from you. If it's a mutation that's been well-described in the literature to be fitting with Duchenne, for example. Dr Jayaraman: Absolutely. Dr Nevel: So, after you confirm the diagnosis through genetic testing---and let's say, you know, whether or not you do a muscle biopsy or not, after you know the diagnosis is a dystrophinopathy---how do you counsel the families and your patients? What are the most important points to relay to families, especially in that initial phase where the diagnosis is being made? Dr Jayaraman: This is a lot of what we do in pediatric neurology in general, right? So, I actually picked up this approach from the pediatric hematology oncology specialists at Boston Children's. They had this concept of a day-zero conversation, which is the day that you disclose the life-changing diagnosis or potentially, at some point, terminal diagnosis to a family. And some of the key components of that are a not beating around the bush, telling them what the diagnosis is, and then letting them have whatever emotional response they're going to have in the moment. And you may not get much further than that, but honestly, you want them to take away, this is what my child has. I did not do anything to cause this, nor could I have done anything to prevent this. Because often for these genetic conditions, there's a lot of guilt, a lot of parental guilt. So, you want to try and assuage that as much as possible. And then to know that they're not going to be alone on this journey; that, you know, they don't have to have it all figured out right then, but we can always come back and answer any questions they have. There's going to be a whole team of specialists. We're going to help the family and the kid manage this condition. Those are sort of my big takeaways that I want them to get. Dr Nevel: Right. And that segues into my next question, which is, who is part of that team? I know that these teams that help take care of people with dystrophinopathies and other muscle disorders can be very large teams that span multiple specialists. Can you talk a little bit more about that for this group of patients? Dr Jayaraman: Of course. So, the neuromuscular neurologist, really, our role is in coordinating the diagnosis, the initiation of any disease-specific treatments, and coordinating care with a whole group of specialists. So, we're sort of at the center of that, but everyone else is equally important. So, the other specialists include physical therapists; occupational therapists; rehab doctors or physiatrists; orthotists who help with all of the many braces and other devices that they might need, wheelchairs; pulmonology, of course, for managing the respiratory manifestations of this. It becomes increasingly important over time, and they are involved early on to help monitor for impending respiratory problems. Cardiac manifestations, this is huge and something that you should be thinking about even for your female carriers, the mother of the patient you're seeing in the clinic, or your patient who comes to adult clinic with asymptomatic hyperCKemia. if you end up making a diagnosis of DMD carrier for those patients, or if you make a Becker diagnosis, the cardiac surveillance is even more important because the cardiac involvement can be out of proportion to the skeletal muscle weakness. And of course, extremely important for the Duchenne patients as well. Endocrinologists are hugely important because in the course of treating patients with steroids, we end up giving them a lot of iatrogenic endocrinologic complications. Like they might have delayed puberty, they might have loss of growth, of height; and of course metabolic syndrome. So, endocrinology is hugely important. They're also important in managing things like fracture prevention, osteoporosis, prescribing bisphosphonates if necessary. Nutrition and GI are also important, not just later on when they might need assistance to take in nutrition, whether that's through tube feeds, but also earlier on when we're trying to manage the weight. Orthopedics, of course, for the various orthopedic complications that patients develop. And then finally, a word must be said for social work and behavioral and mental health specialists, because a lot of this patient population has a lot of mental health challenges as well. Dr Nevel: After you give the diagnosis, you've counseled the patient and families and you've had those kind of initial phase discussions, the day-zero discussion, when you start getting into discussions or thoughts about management, disease-specific medication. But what are the main categories of the treatment options, and maybe how do you kind of approach deciding between treatment options for your patients? Dr Jayaraman: So, there are two broad categories that I like to think about. So, one is the oral corticosteroids and oral histone deacetylase, or HDAC inhibitors, which share the common characteristic that they are non-mutation specific. And within corticosteroids, patients now have a choice between just Prednisone or Prednisolone, or Deflazacort or Vermilion. The oral HDAC inhibitors are newly FDA-approved as a nonsteroidal therapy in addition to corticosteroids in DMD patients above six years of age. I would say we're in the early phase of adoption of this in clinical practice. And then the other big category of treatment options would be the genetic therapies as a broad bucket, and this would include gene therapy or gene replacement therapy, of which the most famous is the microdystrophin gene therapy that was FDA-approved first on an accelerated approval basis for ages four to eight, and then a full approval in that age group as well as an accelerated approval for all comers, essentially, with DMD. This is obviously controversial. Different centers approach this a bit differently. I think our practice at our site has been to focus on the ambulatory population, just thinking about risk versus benefit, because the risks are not insignificant. So really this is something that should be done by experienced sites that have the bandwidth and the wherewithal to counsel patients through all of this and to manage complications as they arise with regular monitoring. And then another class that falls within this broader category would be the Exon-skipping therapies. So as the name suggests, they are oligonucleotides that cause an Exon to be skipped. The idea is, if there is a mutation in a particular Exon that causes a frame shift, and there's an adjacent Exon that you can force skipping of, then the resulting protein, when you splice the two ends together, will actually allow restoration of the reading frame. I think the picture I want to paint is that there's a wide range of options that we present to families, not all of which everyone will be eligible for. And they all have different risk profiles. And I really think the choice of a particular therapy has to be a risk-benefit decision and a shared decision-making process between the physician and the family. Dr Nevel: What is going on in research in this area? And what do you think will be the next big breakthrough? I know before we started the recording you had mentioned that there's a lot of things going on that are exciting. And so, I'm looking forward to hearing more. Dr Jayaraman: Of course. So, I'll be as quick as I can with this. But I mentioned that next-generation Exon skipping therapies, I think the hope is that they will be better at delivering the Exon skipping to the target tissue and cells and that they might be more efficacious. I'm also excited about next-generation gene therapies that might target muscle more specifically and hopefully reduce the off-target effects, or combination use of gene therapies with other immunosuppressive regimens to improve the safety profile and maybe someday allow redosing, which we cannot do currently. Or potentially targeting the satellite cells, which are the muscle stem cells, again, to improve the long term durability of these genetic therapies. Dr Nevel: That's great, thank you for sharing. Thank you so much for talking to me today about your article. I really enjoyed learning more about the dystrophinopathies. Today I've been interviewing Dr Divya Jayaraman about her article on the dystrophinopathies, which she wrote with Dr Partha Ghosh. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Please be sure to check out the Continuum Audio episodes from this and other issues. Also, please read the Continuum articles for more details than what we were able to get to today during our discussion. Thank you, as always, so much to the listeners for joining us today, and thank you, Divya, for sharing all of your knowledge with us today. Dr Jayaraman: Thank you so much for having me on the podcast. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

We talk with physiologist Elliot Jenkins about how passive heat acclimation boosts VO2 max, hemoglobin mass, and cardiac function in trained runners without adding mechanical training load. Practical protocols, safety tips, and open research questions round out a clear, actionable guide to using heat wisely.• Elliot's path from Otago to a PhD in the UK• Why passive heat instead of exercising in heat• Hematology: plasma volume expansion • Cardiac changes: larger end-diastolic volume and stroke volume• VO2 max and speed gains in trained runners• Practical protocol: time, temperature, frequency, hydration• Safety: dizziness, slow exits, supervision, low blood pressure• Dose-response unknowns and hot-climate athletes• Heat vs cold and contrast for recovery and adaptation• Where to find Elliot's paper and social links (see below).Follow Elliott Jenkins on X @E_J_Jenkins His paper is published here: https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP289874

If the Bears don't finish me off, my cats might. This week I dive into their turf war with the neighborhood wanderer, the sweet revenge I scored on my son (so funny I nearly blacked out from laughter), and the arrival of Thanksgiving is here!Check out the podcast and all the fun at www.thedailylifeoffrank.com--------------------------------------------------------------------------------------------Let's connect! Find all my social channels here: https://linktr.ee/thedailylifeoffrank

A story of calm confidence, healing, and letting go of perfection. Episode #233 What happens when you stop chasing perfection and start trusting your body? In this heartfelt conversation, Audrey shares with Coach Lisa how she moved from fear and confusion to calm confidence by embracing nourishment, community, and self-compassion. Audrey's journey reminds us that fasting isn't just about hours — it's about listening to your body, releasing perfectionism, and keeping "a hand on the wagon," even when life gets messy. What you'll learn: Why fasting alone wasn't enough for Audrey The mindset shift that helped her release perfectionism How she advocated for herself through confusing medical advice The practices that improved her sleep, confidence, and cardiac markers How she navigates social eating, travel, and cravings with ease Books mentioned in this episode: The Paleo Cure — Chris Kresser Adrenal Transformation Protocol — Izabella Wentz Fast Like a Girl — Dr. Mindy Pelz   The transcript for this episode is available on our website:

On this episode of the Donut of Destiny, hosts Sotirios Evangelou, MD, FSCCT and Nisha Hosadurg , MBBS speak with guest Alan Vainrib, MD on how computational fluid dynamics (CFD) is emerging as a powerful research tool for understanding blood-flow behavior in structural heart disease. Using CT/MRI-based models, CFD can simulate pressures, velocities, shear stress and even post-procedure hemodynamics — offering new possibilities for evaluating aortic stenosis, planning TAVR and guiding mitral, tricuspid and LAAO interventions.

On today's show: At what temperature do you stop wearing shorts? 02:31 – Detroit Lions narrowly defeat Giants, and the season is on the line The "Cardiac Cats" deliver another stressful win: the Lions barely get by the Giants. Jer and Fletcher break down the wild ride that is the Jameis Winston experience ("more fun when it's not your team on the line!"), and how Jamir Gibbs stepped up in historic fashion. Deep dive into what's working and what isn't—especially a candid convo about Jared Goff, the offensive coordinator, and whether the Lions are too predictable. The hosts highlight what must improve for Detroit with national eyes on them for Thanksgiving against the Packers—a critical NFC North matchup. Both agree: If the Lions want a real shot at the playoffs, they basically need to win out.  11:12 – Detroit Pistons: 12-Game Win Streak and Rising Hopes The Pistons are HOT: 14-2 with a 12-game win streak, taking down Milwaukee on the road (even if Giannis was out). "Are the Pistons for real?" Discussion weighs schedule quality, team growth, the impact of new players, and how Detroit is earning national respect. Local pride watch: Shoutout to Ryan Rollins (Macomb Dakota) leading Milwaukee in the absence of their stars. Being able to expect the Pistons to win games, not just "play hard"—Detroit fans everywhere can relate how good this feels! Call to listeners for vintage Pistons gear for the studio. 18:11 – Red Wings: "Wings in Flight" and Atlantic Division Leaders Quick coverage of the Red Wings' strong season—they're leading the Atlantic and scoring with flash. Props to Dylan Larkin, DeBrincat, and Lucas Raymond, plus some talk about the Yzerplan paying off. 19:35 – Stephen Carroll retires as DCFC Captain for Front Office Role Longtime Detroit City FC captain Stephen Carroll announces retirement from the pitch but stays with the club in a (yet-to-be-named) front office role. Feedback as always - dailydetroit -at- gmail -dot- com or leave a voicemail 313-789-3211. Follow Daily Detroit on Apple Podcasts: https://podcasts.apple.com/us/podcast/daily-detroit/id1220563942 Or sign up for our newsletter: https://www.dailydetroit.com/newsletter/ Support us on Patreon: https://www.patreon.com/DailyDetroit    

Laurence & Spiegs react to another crazy Bulls victory last night a 122-121 win over Portland.

CardioNerds (Dr. Kelly Arps, Dr. Naima Maqsood, and Dr. Elizabeth Davis) discuss chronic AF management with Dr. Edmond Cronin. This episode seeks to explore the chronic management of atrial fibrillation (AF) as described by the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. The discussion covers the different AF classifications, symptomatology, and management including medications and invasive therapies. Importantly, the episode explores current gaps in knowledge and where there is indecision regarding proper treatment course, as in those with heart failure and AF. Our expert, Dr. Cronin, helps elucidate these gaps and apply guideline knowledge to patient scenarios. Audio editing for this episode was performed by CardioNerds intern Dr. Bhavya Shah. CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Review the guidelines- Catheter ablation is a Class I recommendation for select patient groups  Appropriately recognize AF stages- preAF conditions, symptomatology, classification system (paroxysmal, persistent, long-standing persistent, permanent)  Be familiar with the EAST-AFNET4 trial, as it changed the approach of rate vs rhythm control  Understand treatment approaches- lifestyle modifications, management of comorbidities, rate vs rhythm control medications, cardioversion, ablation, pulmonary vein isolation, surgical MAZE  Sympathize with patients- understand their treatment goals  Notes Notes: Notes drafted by Dr. Davis.    What are the stages of atrial fibrillation?   The stages of AF were redefined in the 2023 guidelines to better recognize AF as a progressive disease that requires different strategies at the different therapies  Stage 1 At Risk for AF: presence of modifiable (obesity, lack of fitness, HTN, sleep apnea, alcohol, diabetes) and nonmodifiable (genetics, male sex, age) risk factors associated with AF  Stage 2 Pre-AF: presence of structural (atrial enlargement) or electrical (frequent atrial ectopy, short bursts of atrial tachycardia, atrial flutter) findings further pre-disposing a patient to AF  Stage 3 AF: patient may transition between these stages  Paroxysmal AF (3A): intermittent and terminates within ≤ 7 days of onset  Persistent AF (3B): continuous and sustained for > 7 days and requires intervention  Long-standing persistent AF (3C): continuous for > 12 months   Successful AF ablation (3D): freedom from AF after percutaneous or surgical intervention  Stage 4 Permanent AF: no further attempts at rhythm control after discussion between patient and clinician   The term chronic AF is considered obsolete and such terminology should be abandoned   What are common symptoms of AF?   Symptoms vary with ventricular rate, functional status, duration, and patient perception  May present as an embolic complication or heart failure exacerbation  Most commonly patients report palpitations, chest pain, dyspnea, fatigue, or lightheadedness. Vague exertional intolerance is common  Some patients also have polyuria due to increased production of atrial natriuretic peptide  Less commonly can present as tachycardia-associated cardiomyopathy or syncope  Cardioversion into sinus rhythm may be diagnostic to help determine if a given set of symptoms are from atrial fibrillation to help guide the expected utility of more aggressive rhythm control strategies.   What are the current guidelines regarding rhythm control and available options?  COR-LOE 1B: In patients with reduced LV function and persistent (or high burden) AF, a trial of rhythm control should be recommended to evaluate whether AF is contributing to the reduced LV function   COR-LOE 2a-B: In patients with reduced LV function and persistent (or high burden) AF, a trial of rhythm control should be recommended to evaluate whether AF is contributing to the reduced LV function. In patients with a recent diagnosis of AF (

Thursday Hour 1: Is Sean a movie snob? Tommy Birch & the Cardiac Bulls

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Become a member of The Real Science of Sport Supporters Club to show your support and have your say. A perk of membership is Discourse, our community that chats about training, sports science, physiology and news.Show notesA midweek whip around the world of sport, with some sports science and management insights on stories making headlines this week. We cover:The LA 2028 Olympic Track and Field programme was announced last week. It features three 100m races on one day for the women, and no option for a 400m/400m hurdle double, are among the surprises. We discuss the effects on athletes and the missed opportunitiesTriathlon's T100 series was plunged into chaos with miscounted laps, result changing decisions, and even a vote on whether rules were applied to the satisfaction of athletes. We discuss the fiasco in DubaiBoxing continues its (d)evolution to WWE, with a fight announced between Anthony Joshua and Jake Paul. A gimmick, for sure. Too dangerous? We discussWorld Rugby announced a new calendar for 2026, aimed at giving more relevance and meaning to Tour matches. The schedule has pros and cons, creating a travel load for teams that will require some accommodation for player welfareAnd finally, cardiac events among spectators at last week's ATP Finals are the trigger for a short discussion about the risks of WATCHING sport, with some interesting studies showing how risk increases when people are invested in the resultOther linksThe paper studying cardiac arrests at Gillette StadiumThe cardiac event risk is slightly higher in football in the NetherlandsLosing, but not winning, a Superbowl increases the risk of cardiovascular death Hosted on Acast. See acast.com/privacy for more information.

In this episode Sandy Vance sits down with Dr. Kenneth Stein, Senior Vice President and Global Chief Medical Officer at Boston Scientific, to explore how artificial intelligence is revolutionizing cardiology from diagnosis to treatment.Dr. Stein shares how Boston Scientific is tackling one of healthcare's biggest challenges: too much data and too little insight. From AI-driven heart monitors that detect dangerous rhythms before doctors can see them, to tools that democratize expert-level cardiac imaging, to predictive algorithms that warn clinicians of heart failure weeks before hospitalization. Tune in to hear how AI is not replacing doctors but empowering them, why clinical rigor still matters in the age of algorithms, and what it means for the future of cardiology.In this episode, they talk about:What it means to have too much dataThree key use cases for AI in cardiologyScaling expertise with BeatLogicDemocratizing Expertise with Avigo PlusPredicting outcomes with HeartlogicAI transforms raw data into actionable insights that improve patient outcomes.Radiology and cardiology are examples of how AI enhances (not replaces) medical professionals.Clinicians who embrace AI will outperform those who don't.Ongoing education on AI's role, limits, and evidence base is crucial for healthcare providers.A Little About Kenneth:Kenneth Stein is senior vice president and global chief medical officer at Boston Scientific. In this role, he has oversight for the clinical trials, medical safety and medical affairs functions and is responsible for ensuring a cohesive clinical community of practice across the company. Prior to Boston Scientific, Stein held the position of associate director of clinical cardiac electrophysiology at Weill Cornell Medical Center and associate professor of medicine at Cornell University. Stein is a graduate of Harvard College (in economics) and New York University School of Medicine. He is widely published, having authored more than 160 papers in the peer reviewed medical literature.  

Commentary by Dr. Jian'an Wang.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251370475

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251336314

Gridiron Report: Cardiac Bears Pull Off Another Late Comeback full 144 Mon, 17 Nov 2025 15:26:32 +0000 bDMmk1XDQr1fno2oUr5VGXhBVxWiACuT news Chicago All Local news Gridiron Report: Cardiac Bears Pull Off Another Late Comeback A dive into the top headlines in Chicago, delivering the news you need in 10 minutes or less multiple times a day from WBBM Newsradio. 2024 © 2021 Audacy, Inc. News False https://player.amperwavepodcast

Gridiron Report: Cardiac Bears Pull Off Another Late Comeback full 144 Mon, 17 Nov 2025 15:26:32 +0000 bDMmk1XDQr1fno2oUr5VGXhBVxWiACuT news Chicago All Local news Gridiron Report: Cardiac Bears Pull Off Another Late Comeback A dive into the top headlines in Chicago, delivering the news you need in 10 minutes or less multiple times a day from WBBM Newsradio. 2024 © 2021 Audacy, Inc. News False https://player.amperwavepodcast

Gridiron Report: Cardiac Bears Pull Off Another Late Comeback full 144 Mon, 17 Nov 2025 15:26:32 +0000 bDMmk1XDQr1fno2oUr5VGXhBVxWiACuT news Chicago All Local news Gridiron Report: Cardiac Bears Pull Off Another Late Comeback A dive into the top headlines in Chicago, delivering the news you need in 10 minutes or less multiple times a day from WBBM Newsradio. 2024 © 2021 Audacy, Inc. News False https://player.amperwavepodcast

We would love to hear from you! Please send us your comments here. --------This Christmas, you can shine the light of Christ into places of darkness and pain with a purchase from the Joni and Friends Christmas catalog. You are sending hope and practical care to people with disabilities, all in the name of Jesus! Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Sudden cardiac arrest is a global disaster that rivals the recent viral pandemic in scope. Cardiac arrest is by far the number one killer worldwide according to every public health agency of note. Over the years, treatment of this problem has a less than 4 or 5 percent survival rate with only minor incremental changes to treatment modalities.

This Week your hosts Hall of Fame ref JHawk, JGold & Charly Butters discuss Jgolds dinner, who will have a cardiac event first, making sloppy steaks, Butters doing Whatnot for Monsters in the Toybox for the first time. JGold is going to the PWJunkie show this weekend and as a special game this week the boys use the PWI Women's 250 to draft 10 talents each that will be put into a tournament to crown a winner! Then they review the West Coast Pro/ Prestige show "Strength Beyond Strength" and so much more!

Evolving Treatment Landscape in Transthyretin Cardiac Amyloidosis   Guest: Rosalyn Adigun, M.D., Pharm.D. Host: S. Allen Luis, M.B.B.S., Ph.D.   In this episode of Mayo Clinic's “Interviews With the Experts,” Dr. Allen Luis interviews Dr. Rosalyn Adigun on transthyretin cardiac amyloidosis. Listeners will come away with a detailed overview of the evolution of treatment options for patient diagnosed with transthyretin amyloid cardiomyopathy, highlighting historical perspectives, early registration studies, current treatment options, and an outlook on future directions in the management of transthyretin cardiac amyloidosis.   Topics Discussed: Overview of the historical perspectives on the diagnosis and management of transthyretin amyloidosis. Current treatment options available for transthyretin amyloid cardiomyopathy, and factors that should guide a clinician's decision regarding the choice of therapy. Treatment options in the coming years. Ongoing research initiatives in the management of cardiac amyloidosis.    Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.

Time to get up with a Steelers stinker! Rodgers roasted on the coast! Are the playoffs a pipe dream for Pittsburgh? Smart money says yes! Meanwhile - a Miami Meltdown - do Josh and the Bills shuffle back to Buffalo locked out in the AFC East? And - oh Cardiac Caleb is clutch! The Bears bounce back again - what did their comeback mean for them, and the coach on the other side?! Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, Sam Ashoo, MD and Lara Zibners, MD discuss the August 2025 Pediatric Emergency Medicine Practice article, Diphtheria, Pertussis, and Tetanus: An Update of Evidence-Based Management of Pediatric Patients in the Emergency Department Introduction and guest backgroundHost welcome, show contextDr. Lara Zibners' credentialsEB Medicine involvementPersonal stories and clinical experienceMemorable tetanus and pertussis casesVaccine advocacyRare disease encountersDiphtheria: overview, presentation, treatmentToxigenic vs. non-toxigenic, “bull neck”Cardiac, neurologic complicationsAntitoxin, antibiotics, public healthPertussis: symptoms, vaccine, treatment“100-day cough,” apnea in infantsWaning immunity, boostersAzithromycin, treat contactsTetanus: risk, presentation, managementClostridium ubiquity, no outbreaksMuscle spasms, autonomic instabilityAirway, sedation, antibioticsKey ED takeaways and pearlsEarly suspicion, isolationICU admission for severe casesVaccination, reportingResources and article summaryAppendix, clinical pathwayebmedicine.net referenceCME, further readingGuest's podcast plug and closing remarks“Unstable Vitals” podcastWhere to listenThank you, sign-offCheck out Dr Zibner's podcast Unstable VitalsEmergency Medicine Residents, get your free subscription by writing resident@ebmedicine.net

Matt Peck, the Co-Host of the CHGO Bulls Podcast, joins Mario Herron for another action-packed episode of Bleav in Bulls. The two dive into the Bulls' thrilling win over the Philadelphia 76ers, breaking down what went right, who stepped up, and why this team continues to live up to the “Cardiac Bulls” nickname. They discuss the impressive rise of Josh Giddey and how his recent play could shake up the landscape of the Eastern Conference. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Beta-blockers offer no survival benefit for most heart attack patients with normal heart function, even though they're still widely prescribed Women face higher risks on beta-blockers, including nearly double the risk of death when given higher doses, while men show no measurable harm or benefit Side effects such as fatigue, dizziness, depression, and sexual dysfunction often burden patients without providing meaningful protection The real root of heart disease lies in damaged mitochondria, which are overwhelmed by linoleic acid (LA) from vegetable oils found in most processed foods You can protect your heart by reducing LA, eating the right kinds of carbohydrates, walking daily, getting safe sunlight, and tracking your HOMA-IR score

These Dawgs are forcing us to love them despite giving us heart attacks week after week. Kirby has these "Cardiac Kids" in a great position as we come down the final stretch of the season. We've still got two, big ranked matchups with Texas and Tech remaining. But this week, our focus is solely on the Bulldogs from Mississippi. Those noon games can be a bit tricky. It's not a great spot for either team, but I'd put my money on Kirby having his Bulldogs more prepared than his opponent coming into this one.GO Dawgs! Beat the Dogs!Follow here for updates:Instagram: ⁠⁠⁠⁠@callingthedawgspod⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠Calling the Dawgs Podcast⁠⁠⁠⁠Youtube: ⁠⁠⁠⁠Calling the Dawgs

The Cardiac Bulls strike again! Mario Herron breaks down Chicago's insane 24-point comeback win and what it means for the team moving forward. Plus, Pat Boyle from Infinity Sports Network joins the show to give his take on the Bulls' resilience, the locker room's mindset, and whether this squad can finally find consistency. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The causes, physiology, signs & symptoms, and treatment of cardiac tamponade as an ACLS H&T reversible cause of cardiac arrest.When blood, or other fluids, accumulate in the sac around the heart it's called a cardiac tamponade or pericardial tamponade.The effects of tamponade on the electrical system and chambers of the heart.Cardiac tamponade can be acute or chronic and caused by traumatic, iatrogenic, or pathological etiologies.Common traumatic events, medical procedures, and diseases that can result in a pericardial tamponade.Signs & symptoms of cardiac tamponade.Treatment of cardiac tamponade with pericardiocentesis.For additional information on cardiac tamponade, check out the Pod Resources page at PassACLS.com.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Free Prescription Discount Card - Get your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Other ACLS-related resources: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Radiation Therapy and its Effect on the Heart and Cardiac Devices   Guest: Nicholas Tan, M.D., M.S. Host: Anthony H. Kashou, M.D.   Mayo Clinic electrophysiologist Dr. Nicholas Tan joins Dr. Anthony Kashou on this episode of “ECG Making Waves” to discuss how radiation therapy can impact the heart and heart rhythm. After listening to this podcast, listeners will have developed awareness of the complexities behind managing cardiac devices in cancer patients.   Topics Discussed: What effect does radiation therapy have on the heart? What arrhythmias can be seen with radiation therapy? How can radiation therapy impact cardiac device management? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Contributor: Travis Barlock, MD Educational Pearls: Quick Statistics on Electrical Burns: Electrical burns compose roughly 2 to 9% of all burns that come into emergency departments. The majority of patients who receive electrical burns are male, typically aged 20's to 30's, accounting for 80 to 90% of all electrical burn victims. The majority of burns are linked to occupational exposure. The upper extremities are more commonly impacted by electrical burns, accounting for 70 to 90% of entry points into the body during an exposure. What are some of the key considerations in electrical burns? Unlike chemical or fire/heat related burns, electrical burns have the potential to cause significant internal damage that may not be physically appreciated externally. This damage can include, but is not limited to: Cardiac dysthymias (PVCs, SVT, AV block, to more serious ventricular dysrhythmias such as ventricular fibrillation or ventricular tachycardia). Deep tissue injury resulting in rhabdomyolysis from the initial surge of electricity Rare cases of compartment syndrome What are the treatment considerations for patients who suffer electrical burns? Remembering that cutaneous findings associated with burns may underestimate the severity of the injury, with deeper structures being more likely to be involved as the voltage of the burn injury is directly correlated to severity. Manage the patient's airway, breathing, and circulation as always, and conduct further workup into potential cardiac involvement with EKGs, as well as analysis of the extremities where entry occurred for muscle breakdown and compartment syndrome. Clinical Pearl on Voltage and Current: Voltage can be thought of being equivalent to pressure in a fluid/liquid system. Higher voltages are equivalent to higher pressures, but the ultimate damage delivered to the system is from the rate of delivery/speed of the electrical energy surging (current) through the body. Current is dependent on the tissue it is travelling through, with different tissues having differing electrical resistances. Tissues like the stratum corneum of the skin and the human bone confer the most resistance (thus lower current) whereas skeletal muscle confers lower electrical resistance (thus higher current) due to water and electrolyte content, which is why injuries like rhabdomyolysis are possible and increase with increasing voltage. References Khor D, AlQasas T, Galet C, et al. Electrical injuries and outcomes: A retrospective review. Burns. 2023;49(7):1739-1744. doi:10.1016/j.burns.2023.03.015 Durdu T, Ozensoy HS, Erturk N, Yılmaz YB. Impact of Voltage Level on Hospitalization and Mortality in Electrical Injury Cases: A Retrospective Analysis from a Turkish Emergency Department. Med Sci Monit. 2025;31:e947675. doi:10.12659/MSM.947675 Karray R, Chakroun-Walha O, Mechri F, et al. Outcomes of electrical injuries in the emergency department: epidemiology, severity predictors, and chronic sequelae. Eur J Trauma Emerg Surg. 2025;51(1):85. doi:10.1007/s00068-025-02766-1 Faes TJ, van der Meij HA, de Munck JC, Heethaar RM. The electric resistivity of human tissues (100 Hz-10 MHz): a meta-analysis of review studies. Physiol Meas. 1999;20(4):R1-10. doi:10.1088/0967-3334/20/4/201 Summarized by Dan Orbidan, OMS2 | Edited by Dan Orbidan and Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate

Dr. Arun Sharma Monday 10-27-25 Space ShowQuick Summary:Our program focused on the establishment and operations of Cedars-Sinai's new Space Medicine Research Center, including its research programs, educational components, and institutional support. Arun discussed their stem cell research initiatives, particularly the creation of 3D heart tissue organoids grown in microgravity on the ISS, and explained their approach to training astronauts and conducting space-based medical research. The conversation covered the potential of AI and telemedicine in space missions, regulatory challenges in stem cell research, and the future opportunities presented by commercial space stations for conducting biomedical research. David and Arun were joined by participant Dr. Sherry Bell.Detailed Summary:David and Dr. Sherry Bell discussed the establishment of the Center for Space Medicine Research at Cedars-Sinai, led by Arun. Arun confirmed the center's functionality and its institutional support, emphasizing its research and educational components. After Arun was welcomed back to The Space Show to discuss Cedars-Sinai Medical Center's new Space Medicine Research Center. Arun explained that the center, established about a year ago, builds on their 10 years of work in stem cell and biomanufacturing research, including 8 missions to the ISS. He noted that the center has both research and educational components, offering courses in space medicine and biosciences as part of their master's and PhD programs. Arun emphasized their institutional support and goal to become an academic partner for the growing private space industry in Los Angeles.Arun discussed Cedars' expansion beyond cardiovascular focus to broader biomanufacturing and space research, with plans to establish a clinical arm leveraging their hospital's expertise. He mentioned ongoing conversations with local space industry players in LA, though details are not yet public. Arun also outlined their vision for a comprehensive space medicine program, including pre-flight workups, in-flight diagnostics, and post-flight checkups, while acknowledging the need for space medical training for their network of providers.Arun further discussed his research on 3D heart tissue, or cardiac organoids, created from induced pluripotent stem cells (iPSCs). He explained that these tissues are grown in microgravity on the ISS, as microgravity may improve their growth compared to simulated microgravity on Earth. Arun clarified that the iPSCs and necessary chemicals were launched on SpaceX 33 in August and are now orbiting Earth. David inquired about astronaut training, and Arun explained that they work with engineers and partners like BioServe Space Technologies to train astronauts, as most are not life scientists. Arun expressed a desire for more direct communication with astronauts in the future.The discussion then focused on stem cell research and space medicine training. Arun explained that stem cells are sourced from de-identified donor samples at Cedars-Sinai, with consent for medical research use. The long-term goal is to create patient-specific bioengineered organs, starting with heart tissues, though this remains an area of ongoing research. Arun clarified that the initial training program will focus on biosciences for research scientists, with plans to expand to clinical training in the future.Arun did talk about the potential of AI and telemedicine in supporting deep space missions, emphasizing the value of human-focused research over animal studies. He clarified that his lab uses patient-specific stem cell models, focusing on human biology, and does not work with embryonic stem cells. Arun also addressed the cost and funding challenges of conducting research in space, mentioning partnerships with government agencies and the need to explore alternative funding sources for future collaborations. David inquired about simulating microgravity studies, to which Arun explained that while some ground-based simulations exist, they do not perfectly replicate the conditions of true space microgravity.Arun explained that the stem cell research at Cedars Space Lab involves creating three-dimensional organoids to study human biology and potentially identify new drugs, but emphasized that these cells cannot be transplanted back into people due to ethical and regulatory constraints. He clarified that the research is outcome-oriented, focusing on whether stem cells can be improved in space, with the goal of creating better models for understanding heart development and drug efficacy. David raised concerns about potential regulatory differences between countries, particularly regarding stem cell research, and Arun acknowledged that while the US has strict guidelines, some international research may go unpublished, making it difficult to track all ongoing work in this field.Arun discussed his work as a stem cell biologist and highlighted the potential of space biology research, mentioning a recent publication by UC San Diego on growing cancer cells in space. He expressed concerns about the transition from the ISS to commercial space stations, acknowledging the ISS's valuable contributions to research but seeing an opportunity for the commercial industry to fill the gap. Arun also considered the possibility of conducting research on a commercial space station, emphasizing the potential for more biomedical researchers in space and the possibility of accelerated training in a private space capacity. He expressed interest in the idea of conducting his own research on a private space station, such as SpaceX's Starship, and noted the importance of access and opportunities for further research.Arun discussed the differences between microgravity and partial gravity environments in space, highlighting the potential for developing unique therapeutic options that may only be applicable in space. He explained that while some treatments could be brought back to Earth, others might require patients to travel to space for treatment. Arun also touched on the current state of stem cell research, including clinical trials for various applications, and expressed optimism about future advancements in bioprinting and organoid manufacturing in space. He emphasized the importance of personalized medicine using patient-specific stem cells and encouraged continued interest in both stem cell and space biology research.Be sure to see the video of this program at doctorspace.substack.com.Special thanks to our sponsors:Northrup Grumman, American Institute of Aeronautics and Astronautics, Helix Space in Luxembourg, Celestis Memorial Spaceflights, Astrox Corporation, Dr. Haym Benaroya of Rutgers University, The Space Settlement Progress Blog by John Jossy, The Atlantis Project, and Artless EntertainmentOur Toll Free Line for Live Broadcasts: 1-866-687-7223 (Not in service at this time)For real time program participation, email Dr. Space at: drspace@thespaceshow.com for instructions and access.The Space Show is a non-profit 501C3 through its parent, One Giant Leap Foundation, Inc. To donate via Pay Pal, use:To donate with Zelle, use the email address: david@onegiantleapfoundation.org.If you prefer donating with a check, please make the check payable to One Giant Leap Foundation and mail to:One Giant Leap Foundation, 11035 Lavender Hill Drive Ste. 160-306 Las Vegas, NV 89135Upcoming Programs:Broadcast 4455 ZOOM: Arkisys CEO David Barnhart | Sunday 02 Nov 2025 1200PM PTGuests:ZOOM, Dave Barnhart, CEO of Arkisys updates us with interesting news and developments Get full access to The Space Show-One Giant Leap Foundation at doctorspace.substack.com/subscribe

Think heart disease only affects older people? Or that red wine protects your heart?Join host Sandra Peebles with father-son duo and cardiac surgery experts Dr. Joseph T. McGinn Jr. and Dr. Joseph McGinn III as they bust the most common heart health myths. From silent heart attacks in women to the truth about aspirin and red wine — and the groundbreaking McGinn Technique, a minimally invasive heart surgery featured on Grey's Anatomy — discover what's fact, what's fiction, and how to truly protect your heart.What you'll learn:• Why “young and slim” doesn't mean a “healthy heart”• The surprising symptoms of heart disease in women• The truth about daily baby aspirin• Why red wine isn't a heart protector• How the McGinn Technique speeds recoverySubscribe for more expert insights from Baptist HealthTalk.For heart and vascular care at Baptist Health, explore your options and speak with a clinician today.Host:Sandra PeeblesAward-Winning JournalistGuests:Joseph T. McGinn, Jr., M.D.Chief of Cardiac SurgeryBaptist Health Miami Cardiac & Vascular InstituteJoseph McGinn III, M.D.Cardiovascular SurgeonBaptist Health Heart & Vascular Care

Get insights on chest injuries & emergencies from ER physician Dr. Dacia Ticas. Learn about red flags and vital info for athletic trainers. Q: What drew you to emergency medicine, particularly regarding chest injuries and emergencies? A: I liked everything and wasn't sure what to commit to. Emergency medicine allowed me to experience a bit of everything, including a wide range of chest injuries. Q: As an ER physician, what makes you nervous, especially concerning severe chest injuries in children? A: Pulseless children are concerning. Severe cases with children, such as swelling or edema of the airway where a cricothyrotomy might be necessary, are also very serious. Q: For athletic training, what are red flags indicating something is truly wrong with an athlete, beyond just being out of shape, regarding potential chest injuries? A: Being out of shape typically presents as shortness of breath without actual struggle or severe chest pain. Red flags for chest injuries include pale or cyanotic appearance, complaints of severe chest pain, and a visible struggle to breathe. Q: Is an on-field ultrasound something athletic trainers can perform, or is a physician required for assessing chest injuries? A: A physician would be required. While we wish it were seen more often, on-field ultrasound has tremendous value in clarifying life-threatening chest injuries. Q: As athletic trainers are the initial contact for chest injuries, what essential information do you need from us? A: We will conduct our routine workup regardless. Key information includes what actually happened—e.g., getting hit in the throat versus the chest—whether they collapsed or lost consciousness, and how the patient initially presented and communicated their complaints. Q: What kind of chest injuries might take a day or two to fully manifest or be definitively diagnosed? A: Cardiac and pulmonary contusions can take time to develop. Life-threatening issues are typically identified through labs on the day of the incident. Q: Can you explain Commotio cordis in the context of chest injuries? A: Commotio cordis involves the ventricles going out of whack due to a flux of ions being disrupted, which is a chemical issue. This happens in a fraction of a second, as highlighted by the Damar Hamlin incident, which brought athletic training to the forefront for chest injuries. Q: When an athlete experiences chest pain after a hard tackle, when is immediate removal necessary, and when can we "wait and see" for bigger issues related to chest injuries? A: Often, if you ask an athlete if they can return to play a few plays later, they might indicate they cannot or develop a specific spot of noticeable pain. Lingering pain for a few plays, rather than generalized pain, may be a sign for removal due to a bigger issue, particularly with chest injuries. Q: Could you share a surprising ER story related to chest injuries? A: There are many stories. Early in my career, seeing a 4x4 through a chest wall, yet the internal organs were intact, was shocking. As I progressed, medical mysteries became more enticing. DJ Harden's aortic injury after a chest hit, and assessing patient consciousness and bilateral pulse equality, are all crucial in emergency medicine for chest injuries.

This week we review a recent survey study assessing the beliefs of fetal cardiologists and how these may influence the content and conduct of their counseling. Do most fetal cardiologists review all options including intervention, comfort care and pregnancy termination? Should there be a mandate that all do? Is it realistic or appropriate to ask a fetal cardiologist to suggest an option when they do not believe it to be a reasonable or correct choice? We speak with two of the authors of this work and they are Dr. Joanne Chiu of Harvard University and Dr. Caitlin Haxel of The University of Vermont. DOI: 10.1002/pd.6706